Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Sep;23(9):925-937.
doi: 10.1016/S1474-4422(24)00170-4. Epub 2024 Jun 25.

Sleep and sleep disorders in people with Parkinson's disease

Affiliations
Review

Sleep and sleep disorders in people with Parkinson's disease

Alex Iranzo et al. Lancet Neurol. 2024 Sep.

Abstract

Sleep disorders are common in people with Parkinson's disease. These disorders, which increase in frequency throughout the course of the neurodegenerative disease and impair quality of life, include insomnia, excessive daytime sleepiness, circadian disorders, obstructive sleep apnoea, restless legs syndrome, and rapid eye movement (REM) sleep behaviour disorder. The causes of these sleep disorders are complex and multifactorial, including the degeneration of the neural structures that modulate sleep, the detrimental effect of some medications on sleep, the parkinsonian symptoms that interfere with mobility and comfort in bed, and comorbidities that disrupt sleep quality and quantity. The clinical evaluation of sleep disorders include both subjective (eg, questionnaires or diaries) and objective (eg, actigraphy or video polysomnography) assessments. The management of patients with Parkinson's disease and a sleep disorder is challenging and should be individualised. Treatment can include education aiming at changes in behaviour (ie, sleep hygiene), cognitive behavioural therapy, continuous dopaminergic stimulation at night, and specific medications. REM sleep behaviour disorder can occur several years before the onset of parkinsonism, suggesting that the implementation of trials of neuroprotective therapies should focus on people with this sleep disorder.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests MLF received a grant from Region AURA (France) Research and Development and the Société Française de Recherche et Médecine du Sommeil. MLF received a payment honoraria for lectures from Elvie, and financial support for attending meetings from Sos Oygène and Odalys Santé. LMT participated in the board of the American Academy of Sleep Medicine, American Academy of Sleep Medicine Foundation, and American Board of Sleep Medicine. All other authors report no conflict of interests regarding the content of this Review.

MeSH terms

LinkOut - more resources